BridgeMD
Compares treatment options for Ischemic Cardiomyopathy
Official title Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)
ClinicalTrials.gov ID: NCT05888662
What this study is testing
- What it's testing
- Radiofrequency ablation of ventricular tachycardias (VTs) is the gold standard treatment of refractory VTs in patients with ischaemic heart disease. In this setting, ablation is usually performed endocardially.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients over 18 years of age
- 1st radiofrequency ablation of VT complicating ischaemic heart disease
- Patients with an ICD and remote monitoring
- Having, for women of childbearing age, effective contraception until discharge from hospital
- Have given their free and informed consent in writing
You likely can't join if
- History of cardiac surgery compromising the epicardial approach (coronary artery bypass grafting, valve replacements, or other surgeries that may...
- Presence of a left intraventricular thrombus found during pre-procedure imaging
- Anticoagulant therapy that cannot be temporarily discontinued
- Double antiplatelet therapy that cannot be temporarily replaced by single antiplatelet therapy
- History of pericarditis
- Previous thoracic radiotherapy
See the full eligibility criteria
- Patients over 18 years of age
- 1st radiofrequency ablation of VT complicating ischaemic heart disease
- Patients with an ICD and remote monitoring
- Having, for women of childbearing age, effective contraception until discharge from hospital
- Have given their free and informed consent in writing
- are affiliated to or have health insurance
- History of cardiac surgery compromising the epicardial approach (coronary artery bypass grafting, valve replacements, or other surgeries that may have caused pericardial adhesions)
- Presence of a left intraventricular thrombus found during pre-procedure imaging
- Anticoagulant therapy that cannot be temporarily discontinued
- Double antiplatelet therapy that cannot be temporarily replaced by single antiplatelet therapy
- History of pericarditis
- Previous thoracic radiotherapy
- Contraindication to general anaesthesia
- Pregnant or breastfeeding woman
- History of heparin-induced thrombocytopenia type 2 (as injection is required during the procedure)
- Person under legal protection (safeguard of justice, curatorship, guardianship), deprived of liberty, or unable to express consent
The study team makes the final eligibility decision.
Where it's taking place
- Bordeaux, France
- Caen, France
- Clermont-Ferrand, France
- Lille, France
- Lyon, France
- Nantes, France
- Paris, France
- Rennes, France
- Saint-Etienne, France
- Toulouse, France
- Tours, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bordeaux, France; Caen, France; Clermont-Ferrand, France; Lille, France; Lyon, France; Nantes, France and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.